JP2016526021A5 - - Google Patents

Download PDF

Info

Publication number
JP2016526021A5
JP2016526021A5 JP2016513057A JP2016513057A JP2016526021A5 JP 2016526021 A5 JP2016526021 A5 JP 2016526021A5 JP 2016513057 A JP2016513057 A JP 2016513057A JP 2016513057 A JP2016513057 A JP 2016513057A JP 2016526021 A5 JP2016526021 A5 JP 2016526021A5
Authority
JP
Japan
Prior art keywords
composition according
composition
target polypeptide
corrole
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016513057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016526021A (ja
JP6640715B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/037234 external-priority patent/WO2014182868A1/en
Publication of JP2016526021A publication Critical patent/JP2016526021A/ja
Publication of JP2016526021A5 publication Critical patent/JP2016526021A5/ja
Application granted granted Critical
Publication of JP6640715B2 publication Critical patent/JP6640715B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016513057A 2013-05-08 2014-05-08 腫瘍毒性に対する標的コロールおよびmri Expired - Fee Related JP6640715B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361821106P 2013-05-08 2013-05-08
US61/821,106 2013-05-08
PCT/US2014/037234 WO2014182868A1 (en) 2013-05-08 2014-05-08 Targeting corroles for tumor toxicity and mri

Publications (3)

Publication Number Publication Date
JP2016526021A JP2016526021A (ja) 2016-09-01
JP2016526021A5 true JP2016526021A5 (enExample) 2017-06-22
JP6640715B2 JP6640715B2 (ja) 2020-02-05

Family

ID=51864925

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016513057A Expired - Fee Related JP6640715B2 (ja) 2013-05-08 2014-05-08 腫瘍毒性に対する標的コロールおよびmri

Country Status (16)

Country Link
US (2) US9757386B2 (enExample)
EP (2) EP3730155A1 (enExample)
JP (1) JP6640715B2 (enExample)
KR (1) KR20160008523A (enExample)
CN (2) CN105307499B (enExample)
AU (2) AU2014262653B2 (enExample)
CA (1) CA2910030A1 (enExample)
DK (1) DK2993983T3 (enExample)
ES (1) ES2791043T3 (enExample)
IL (1) IL265935B (enExample)
MX (1) MX2015015434A (enExample)
PL (1) PL2993983T3 (enExample)
PT (1) PT2993983T (enExample)
RU (1) RU2674146C2 (enExample)
WO (1) WO2014182868A1 (enExample)
ZA (1) ZA201508092B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9078927B2 (en) 2007-07-06 2015-07-14 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
US10036009B2 (en) 2012-08-03 2018-07-31 Cedars-Sinai Medical Center Isolating traffic-enhancing mutants of drug delivery protein
DK2993983T3 (da) 2013-05-08 2020-05-18 Cedars Sinai Medical Center Målretningskorroler til tumortoksicitet og mri
MX381016B (es) 2014-01-17 2025-03-12 Cedars Sinai Medical Center Composiciones de nanopartículas para su uso en la entrega de una carga útil al cerebro.
MX2016013025A (es) 2014-04-04 2017-04-27 Cedars Sinai Medical Center Focalizacion de cancer de mama her2+ resistente a trastuzumab con una nanoparticula dirigida de her3.
US20200345846A1 (en) * 2017-08-31 2020-11-05 Technion Research & Development Foundation Limited Corrole compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA129822A (en) 1910-08-24 1910-12-13 The John Bertram And Sons Company, Limited Motor controlling apparatus
CA140995A (en) 1912-03-05 1912-06-11 Davydd C. Hughes Type plate mechanism
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
WO2002094318A1 (en) 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
CA2452644C (en) * 2001-07-02 2013-01-22 Technion Research And Development Foundation Ltd. Method for the preparation of selectively-substituted corroles and new substituted corroles
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
US9078927B2 (en) 2007-07-06 2015-07-14 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2009027965A1 (en) * 2007-08-28 2009-03-05 Technion Research And Development Foundation Ltd. Transition metal complexes of corroles for preventing cardiovascular diseases or disorders
WO2009095923A2 (en) * 2008-01-31 2009-08-06 Technion Research And Development Foundation Ltd Corroles for neuroprotection and neurorescue
US8541568B2 (en) 2008-05-24 2013-09-24 Hai Yan Compositions and methods using siRNA molecules for treatment of gliomas
US9012622B2 (en) 2008-12-31 2015-04-21 Patrick Y. Lu Compositions and methods using siRNA molecules and siRNA cocktails for the treatment of breast cancer
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
CN101704820A (zh) * 2009-09-24 2010-05-12 江苏大学 三(4-氯苯基)咔咯化合物及其合成方法
WO2011094335A2 (en) 2010-01-26 2011-08-04 Yale University Microrna signatures predicting responsiveness to anti-her2 therapy
CN103874490A (zh) * 2011-08-15 2014-06-18 工业研究与发展基金会有限公司 咔咯和他汀类药物的组合
US10036009B2 (en) 2012-08-03 2018-07-31 Cedars-Sinai Medical Center Isolating traffic-enhancing mutants of drug delivery protein
DK2993983T3 (da) 2013-05-08 2020-05-18 Cedars Sinai Medical Center Målretningskorroler til tumortoksicitet og mri
MX381016B (es) 2014-01-17 2025-03-12 Cedars Sinai Medical Center Composiciones de nanopartículas para su uso en la entrega de una carga útil al cerebro.
MX2016013025A (es) * 2014-04-04 2017-04-27 Cedars Sinai Medical Center Focalizacion de cancer de mama her2+ resistente a trastuzumab con una nanoparticula dirigida de her3.
CA3025348A1 (en) 2016-05-27 2017-11-30 Cedars-Sinai Medical Center Drug-delivery nanoparticles and treatments for drug-resistant cancer

Similar Documents

Publication Publication Date Title
Araste et al. Peptide-based targeted therapeutics: Focus on cancer treatment
JP2016526021A5 (enExample)
Liu et al. pH-sensitive nano-systems for drug delivery in cancer therapy
Lehner et al. Intelligent nanomaterials for medicine: carrier platforms and targeting strategies in the context of clinical application
JP2017514800A5 (enExample)
EP4335511A3 (en) Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
JP2016535009A5 (enExample)
JP2017521486A5 (enExample)
JP2010270124A5 (enExample)
Mereddy et al. Benzoboroxoles: Synthesis and applications in medicinal chemistry
JP2016538344A5 (enExample)
CN112888458A (zh) Cldn18的抗体和化疗药物的联合治疗
IL292193B1 (en) Anti-b7-h1 antibodies for treating tumors
JP2015536964A5 (enExample)
JP2015530404A5 (enExample)
JP2016528162A5 (enExample)
JP2014508804A5 (enExample)
JP2017508724A5 (enExample)
FI3511004T3 (fi) Yhdistelmävalmisteita syövän hoitoon
Sawant et al. Cancer research and therapy: Where are we today
WO2015154059A3 (en) Targeting trastuzumab-resistant her2+breast cancer with a her3-targeting nanoparticle
JP2019506862A5 (enExample)
JP2016527202A5 (enExample)
JP2014506233A5 (enExample)
RU2015152033A (ru) Нацеленные корролы, проявляющие опухолевую токсичность и предназначенные для мрт